Show
Sort by
-
A cost-effectiveness analysis of low-dose Aspirin in the primary prevention of cardiovascular disease in four European countries
-
Cost-effectiveness of everolimus vs mycophenolate mofetil (MMF) in de novo heart transplant recipients
-
Diagnosis of fibromyalgia and health care resource use in primary care in the UK
-
A model-based cost-utility analysis of lyrica (TM)(pregabalin) versus current pharmaceutical management of peripheral neuropathic pain
-
Modelling the clinical consequences of rimonabant in addition to diet and exercise in abdominally obese patients with type-2 diabetes
-
A multi-country health economic evaluation of N-3 polyunsaturated fatty acids (PUFA) in the secondary prevention after MI
-
A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium
-
Irbesartan is projected to be cost and life saving compared to standard blood pressure control alone fortreatment of patients with type 2 diabetes, hypertension, and microalbuminuria in Spanish, Swedish and Swiss settings
-
An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients in Italy
-
The perceived benefits of dosing schedules for children with ADHD